Core Insights - Akoya Biosciences and Enable Medicine have announced a collaboration to create the largest commercially available single-cell spatial proteomics atlas, which includes over 100 million single cells from more than 8,500 samples across 15+ cancer types [1][2][3] Group 1: Enable Pan-Cancer Atlas Features - The Enable Atlas is a multi-modal dataset built using Akoya's PhenoCycler-Fusion platform, featuring the PhenoCode™ Discovery IO60 panel as foundational data [2] - It includes rich cellular features with up to 60 protein biomarkers, H&E images, spatial transcriptomics measurements, and comprehensive clinical metadata [2][5] - The dataset is curated, standardized, and commercially licensable, providing immediate value to biopharma researchers and AI model developers [3][5] Group 2: Benefits for Biopharma and Research - The Enable Atlas allows biopharma customers to generate new hypotheses, increase statistical power, and identify novel cellular phenotypes at an unprecedented scale [4] - It is designed for discovery and offers unmatched scale and depth with over 100 million spatially profiled single cells [8] - The dataset's analytical capabilities enable biomarker discovery, comparative analysis, and statistical validation in both discovery and translational research [5][6] Group 3: Upcoming Showcase - The Enable Atlas will be showcased at the American Association for Cancer Research (AACR) Annual Meeting, providing attendees with a first look at this new spatial proteomics resource [8][9] - A live demonstration will be available during the event, with team members present to discuss applications in translational research, biomarker discovery, and drug development [9]

Core Insights - Akoya Biosciences has announced a collaboration with the Singapore Translational Cancer Consortium (STCC) for the SUPER study, aimed at identifying biomarkers for immune checkpoint inhibitor responses [1][2] - The study will focus on a unique cohort of 200 patients, including 100 exceptional responders and 100 hyperprogressors, to understand the biological determinants of treatment outcomes [2][4] - The collaboration will utilize Akoya's IO60 panel for spatial proteomic analysis, enhancing biomarker-driven cancer treatment [5][7] Study Objectives - Identify and validate the assay combination and biomarker profile that best predicts response or refractoriness to PD1/PDL1 inhibition [8] - Develop a combinatorial assay kit/model for predicting PD1/PDL1 treatment response for clinical applications [8] - Establish a national biomarker discovery program for extreme responders to cancer treatment [8] Collaboration Significance - The SUPER study represents a national effort to redefine immunotherapy strategies in Singapore, integrating public healthcare and research institutions [4][7] - The partnership aims to bridge spatial proteomics with clinical insights, potentially shaping the future of precision oncology [7] - Akoya's IO60 panel will provide critical insights into the tumor microenvironment, which could lead to more effective cancer treatments and healthcare cost optimization [5][6]